Achillion (ACHN) ACH-3422 Patents Published Today - Deutsche Bank

Deutsche Bank maintained a Buy rating on Achillion Pharmaceuticals (NASDAQ: ACHN) with a price target of $17. Analyst Alethia Young noted US patents for its nuke, ACH-3422, were published today.

"We have gotten many questions from clients in the past around patent status on 3422 so we are circulating the info out today. 3422 (nuke) patents were published today and publicly available in the US. The publishing of the patent is in-line with mgmt guidance for the end of the year. This means that the patent has gone through preliminary steps and has been deemed novel & patentable. Next step is full prosecution which could take a couple of years," said Young.

"Additionally, 3422 has gone through the European search & claims. In these preliminary steps, it was deemed novel and patentable. The International Search Report reference number PCT/US2014/034018," added the analyst.

The Deutsche Bank report included two links (Here and Here.)

For an analyst ratings summary and ratings history on Achillion Pharmaceuticals click here. For more ratings news on Achillion Pharmaceuticals click here.

Shares of Achillion Pharmaceuticals closed at $10.13 yesterday.

You May Also Be Interested In

• Deutsche Bank Downgrades Boyd Gaming (BYD) to Hold
• Citi Upgrades TAL International (TAL) to Buy, sees "strong revenue and earnings growth"
• Stifel Upgrades LeMaitre Vascular (LMAT) to Buy